Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB to ally with Harvard University on medical research

UCB to ally with Harvard University on medical research

1st March 2011

UCB has agreed a new collaboration with Harvard University that will see the pharmaceutical company fund research into new medical advances.

The alliance will involve the provision of up to $6 million (3.68 million pounds) over two years for a number of research projects led by Harvard scientists, while UCB will also lend expertise on antibody generation and medicinal chemistry.

Studies will be focused on drug development pathways and new therapeutic modalities in the fields of central nervous system conditions and immunology, which are both priority areas for UCB.

The first project to be funded by the alliance will involve the development of antibodies against a biological target that could play a role in treating diabetes and metabolic disorders.

Ismail Kola, president of UCB NewMedicines, said: "The aim of our alliance with Harvard is to create a two-way exchange of knowledge and expertise that will facilitate the successful development of innovative new drugs."

Last month, UCB marked European Epilepsy Day by highlighting the success of its drug Vimpat, which has been used to treat more than 100,000 epilepsy patients since its 2008 launch.ADNFCR-8000103-ID-800434743-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.